DBV Technologies (NASDAQ:DBVT) PT Lowered to $5.00

DBV Technologies (NASDAQ:DBVT - Get Free Report) had its price objective dropped by equities researchers at HC Wainwright from $10.00 to $5.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a "buy" rating on the stock.

Separately, StockNews.com initiated coverage on DBV Technologies in a research report on Monday. They issued a "hold" rating on the stock.

DBV Technologies Trading Down 1.5 %

DBVT traded down $0.01 during midday trading on Wednesday, hitting $0.67. The company's stock had a trading volume of 158,730 shares, compared to its average volume of 48,468. DBV Technologies has a 52-week low of $0.65 and a 52-week high of $2.37. The firm has a 50-day moving average price of $0.75 and a two-hundred day moving average price of $0.84. The firm has a market cap of $129.22 million, a P/E ratio of -1.72 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.10. The firm had revenue of $8.88 million during the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same period in the previous year, the firm earned ($0.23) earnings per share. On average, equities analysts expect that DBV Technologies will post -0.88 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

Several large investors have recently made changes to their positions in the business. Cowen AND Company LLC acquired a new position in DBV Technologies during the 4th quarter worth approximately $49,000. Landscape Capital Management L.L.C. acquired a new position in shares of DBV Technologies during the third quarter worth $94,000. Finally, Optiver Holding B.V. boosted its stake in shares of DBV Technologies by 595.2% in the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company's stock valued at $374,000 after purchasing an additional 235,337 shares during the period. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.